Fernand Labrie

Publications

Page 1 of 4, showing 50 records out of 191 total, starting on record 1, ending on 50

Publication Category Year
4761. Zhao, G., Lu, L., Luu-The, V., Fan, Z., Labrie, F., Pelletier, G. (2010) Expression of 5alpha-reductase type 1 in breast cancer and adjacent non-malignant tissue: an immunohistochemical study. Horm Mol Biol Clin Invest. 3:411-415. Breast Cancer 2010
4763. Labrie, F. (2011) Editorial: The major role of androgens in prostate cancer and the need for more efficient blockade. Expert Rev. Endocrinol. Metab. 6:313-316. Breast Cancer 2011
4755. Lu, L., Zhao, G., Luu-The, V., Ouellet, J., Fan, Z., Labrie, F., Pelletier, G. (2011) Expression of 11β-hydroxysteroid dehydrogenase Type 1 in breast cancer and adjacent non-malignant tissue. An immunocytochemical study. Pathol Oncol Res. 17:627-632. Breast Cancer 2011
4754. Labrie, F (2011) DHEA and Cancer Risk or Prevention? In: DHEA (Dehydroepiandrosterone) in Human Health and Aging, R.R.Watson ed., Taylor & Francis Group LLC, publishers, Chapter 12, pp: 153-172. Breast Cancer 2011
4733. Li, S., Han, B., Liu, G., Li, S., Ouellet, J., Labrie, F., Pelletier, G. (2010) Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem. 58:509-15. Breast Cancer 2010
5. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. Breast Cancer 2007
456. Auger, S., Mérand, Y., Pelletier, J.D., Poirier, D., Labrie, F. (1995) Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384. J. Steroid Biochem. Mol. Biol., 52: 547-565. Breast Cancer 1995
91. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol., 3: 665-668. Breast Cancer 1996
485. Bélanger, A., Caron, S., Labrie, F., Naldoni, C., Dogliotti, L., Angeli, A. (1990) Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: Relationships with cyst type. Eur J Cancer, 26: 277-281. Breast Cancer 1990
486. Bélanger, A., Labrie, F., Angeli, A. (1990) Unconjugated glucuronide steroid levels in human breast cyst fluid. In: Biochemistry of Breast Cyst Fluid. Correlation with Breast Cancer Risk. Angeli, A., Bradlow, H.L., Chasalow, F.I. et Dogliotti, L. eds. Ann. N.Y. Acad. Sci. pp 93-100. Breast Cancer 1990
373. Berger, L., El-Alfy, M., Labrie, F. (2008) Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol, 109: 67-80. Breast Cancer 2008
450. Blais, Y., Gingras, S., Haagensen, D.E., Labrie, F., Simard, J. (1996). Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell. Endocrinol., 121: 11-18. Breast Cancer 1996
463. Blais, Y., Sugimoto, K., Carrière, M.-C., Haagensen, D.E., Labrie, F., Simard, J. (1994) Potent stimulatory effect of interleukin-1alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast cancer cells. Int. J. Cancer, 59: 400-407. Breast Cancer 1994
457. Blais, Y., Sugimoto, K., Carrière, M.C., Haagensen, D.E., Labrie, F., Simard, J. (1995) Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. Int. J. Cancer, 62: 732-737. Breast Cancer 1995
451. Blais, Y., Zhao, C., Huber, M., Audette, M., Labrie, F., Poulin, R. (1996) Growth-independent induction of spermidine transport by IL-4 and IL-13 in ZR-75-1 human breast cancer cells. Int. J. Cancer, 67: 532-538. Breast Cancer 1996
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. Breast Cancer 1999
452. Couch, F.J., Rommens, J.M., Neuhausen, S.L., Bélanger, C., Dumont, M., Abel, K., Bell, R., Berry, S., Bogden, R., Cannon-Albright, L., Farid, L., Frye, C., Hattier, T., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J.F., McArthur-Morrison, J., McSweeney, D., Miki, Y., Peng, Y., Samson, C., Schroeder, M., Snyder, S.C., Stringfellow, M., Stroup, C., Swedlund, B., Swensen, J., Teng, D., Thakur, S., Tran, T., Tranchant, M., Welver-Feldhaus, J., Wong, A.K.C., Sjoziua, J., Labrie, F., Skolnick, M.H., Goldgar, D.E., Kamb, A., Weber, B.L., Tavtigian, S.V., Simard, J. (1996) Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics, 36: 86-99. Breast Cancer 1996
425. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. Breast Cancer 1998
416. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. Breast Cancer 1999
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. Breast Cancer 1998
407. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. Breast Cancer 2000
468. Couture, P., Thériault, C., Simard, J., Labrie, F. (1993) Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology, 132: 179-185. Breast Cancer 1993
478. Dauvois, S., Geng, C.S., Lévesque, C., Mérand, Y., Labrie, F. (1991) Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res., 51: 3131-3135. Breast Cancer 1991
501. Dauvois, S., Labrie, F. (1989) Androstenedione and androst-5-ene-3beta, 17beta-diol stimulate DMBA-induced rat mammary tumors-role of aromatase. Breast Cancer Res. Treat., 13: 61-69. Breast Cancer 1989
487. Dauvois, S., Labrie, F. (1990) Effect of adrenal estrogens on the growth of dimethylbenz(a)antracene-induced mammary carcinoma in the rat. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Peripheral Tissues, Normal and Neoplastic Tissues. Ann. New York Acad. Sci. pp 416-418. Breast Cancer 1990
488. Dauvois, S., Li, S., Labrie, F. (1990) Antagonism between androgens and estrogens on the growth of mammary carcinoma in vivo. In: Bradlow, H., Castagnetta, L., d'Aquino, S. et Labrie, F., eds. Steroid Formation, Degradation and Action in Normal, Neoplasic and Peripheral Tissues. Ann. New York Acad. Sci. pp 413-415. Breast Cancer 1990
502. Dauvois, S., Li, S., Martel, C., Labrie, F. (1989) Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 14: 299-306. Breast Cancer 1989
489. Dauvois, S., Simard, J., Dumont, M., Haagensen, D.E., Labrie, F. (1990) Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells. Mol. Cell. Endocrinol. 73: 171-178. Breast Cancer 1990
503. Dauvois, S., Spinola, P.G., Labrie, F. (1989) Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. Eur. J. Cancer Clin. Oncol., 25: 891-897. Breast Cancer 1989
479. de Launoit, Y., Dauvois, S., Dufour, M., Simard, J., Labrie, F. (1991) Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16'a-chloro-3',17β-dihydroxy-estra-1',3',5'-(10')triene-7'a-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res., 51: 2797-2802. Breast Cancer 1991
387. Dimitrakakis, C., Zhou, J., Wang, J., Belanger, A., Labrie, F., Cheng, C., Powell, D., Bondy, C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10: 292-298. Breast Cancer 2003
504. Dumont, M., Dauvois, S., Simard, J., Garcia, T., Schachter, B., Labrie, F. (1989) Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. J. Steroid Biochem., 34: 397-402. Breast Cancer 1989
453. Durocher, F., Shattuck-Eidens, D., McClure, M., Labrie, F., Skolnick, M.H., Goldgar, D.E., Simard, J. (1996) Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum. Mol. Genet., 5: 835-842. Breast Cancer 1996
362. Durocher, F., Simard, J., Ouellette, J., Richard, V., Labrie, F., Pelletier, G. (1997) Localization of the BRCA1 gene expression in adult cynomolgus monkey tissues. J. Histochem. Cytochem., 45: 1173-1188. Breast Cancer 1997
438. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. Breast Cancer 1997
388. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. Breast Cancer 2003
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. Breast Cancer 1999
393. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. Breast Cancer 2002
4691. Han, B., Li, S., Song, D., Poisson-Paré, D., Liu, G., Luu-The, V., Ouellet, J., Li, S., Labrie, F., Pelletier, G. (2008) Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol, 112: 194-200 Breast Cancer 2008
418. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. Breast Cancer 1999
389. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. Breast Cancer 2003
481. Lévesque, C., Mérand, Y., Dufour, J.M., Labrie, C., Labrie, F. (1991) Synthesis and biological activity of new halo-steroidal antiestrogens. J. Med. Chem., 34: 1624-1630. Breast Cancer 1991
408. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. Breast Cancer 2000
473. Labrie, C., Martel, C., Dufour, J.M., Lévesque, C., Mérand, Y., Labrie, F. (1992) Novel compounds inhibit estrogen formation and action. Cancer Res., 52: 610-615. Breast Cancer 1992
160. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. Breast Cancer 1991
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. Breast Cancer 2002
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. Breast Cancer 2006
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. Breast Cancer 2006
355. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. Breast Cancer 2007
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. Breast Cancer 2008
<< previous
| 1 | 2 | 3 | 4 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards